Related Experiment Video
Updated: Jul 31, 2026
06:28
Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
Published on: October 1, 2015
Response in Patients with Chronic HCV Hepatitis to Treatment with Interferon-alpha
Barone1, de Paula Cavalheiro N, Suematsu
1Department of Infectious Diseases, Faculty of Medicine, University of São Paulo.
Summary
Interferon-alpha therapy improved hepatitis C in 33% of patients clinically and 83% histopathologically. This treatment primarily exhibits an antiviral effect, reducing viral cytopathic impact on the liver.
Area of Science:
- Hepatology
- Immunology
- Virology
Background:
- Chronic hepatitis C virus (HCV) infection is a significant cause of liver disease.
- Understanding the therapeutic effects and mechanisms of interferon-alpha in HCV is crucial for patient management.
Purpose of the Study:
- To evaluate the clinical and histopathological efficacy of interferon-alpha in chronic hepatitis C.
- To assess the immunological impact of interferon-alpha treatment on lymphocyte populations.
- To elucidate the mechanism of interferon-alpha's action in treating hepatitis C.
Main Methods:
- Twelve patients with chronic hepatitis C received interferon-alpha for 52 weeks.
- Clinical response, complete blood counts, lymphocyte subsets (CD4+, CD8+), and liver function tests were monitored.
- Liver biopsies with immunohistochemistry were performed pre- and post-treatment in seven patients.
Main Results:
- Thirty-three percent (4/12) of patients showed clinical improvement; 83% (10/12) demonstrated histopathological improvement.
- Total blood lymphocyte counts decreased post-treatment; however, no significant changes were observed in other blood lymphocyte subsets.
- Liver tissue analysis revealed significant reductions in T and CD4+ lymphocytes post-treatment.
Conclusions:
- Interferon-alpha is effective in treating chronic hepatitis C, showing both clinical and histopathological benefits.
- The drug's primary effect appears to be antiviral, reducing viral cytopathic damage rather than modulating immunopathology.
- Further research into interferon-alpha's immunomodulatory effects in liver disease is warranted.
More Related Videos
Related Concept Videos
01:29Immune Response Against Viral Pathogens
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...